

# Clinical Characteristics Predict Recurrence in Borderline Ovarian Tumor Patients with Fertility-Preserving Surgery

Yunan He <sup>1,\*</sup>, Jiaojiao Zhong<sup>2,\*</sup>, Hui Yang <sup>3</sup>, Nianchun Shan<sup>4</sup>, Anran Cheng <sup>5,6</sup>

<sup>1</sup>Reproductive Medical Center, Department of Gynecology and Obstetrics, Tangdu Hospital, Air Force Medical University, Xi'an, Shaanxi, People's Republic of China; <sup>2</sup>Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu, People's Republic of China; <sup>3</sup>Department of Gynecology and Obstetrics, The First Affiliated Hospital of Hunan University of Medicine, Huaihua, Hunan, People's Republic of China; <sup>4</sup>Department of Gynecology and Obstetrics, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; <sup>5</sup>Department of Gynecology and Obstetrics, Xiamen Maluanwan Hospital, Xiamen, Fujian, People's Republic of China; <sup>6</sup>Department of Gynecology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Anran Cheng, Department of Gynecology and Obstetrics, Xiamen Maluanwan Hospital, Dongyao Cun, Maluanwan New Town, Haicang District, Xiamen, Fujian, 361027, People's Republic of China, Tel/Fax +86-592-213 7792, Email chenganr@mail2.sysu.edu.cn; Nianchun Shan, No. 87 Xiangya Road, Hunan, 41008, People's Republic of China, Tel/Fax +86-731-89753999, Email shanncc@csu.edu.cn

**Purpose:** To identify prognostic factors in patients with borderline ovarian tumor (BOT) and establish and validate a nomogram predicting recurrence in BOT patients treated with fertility-preserving surgery.

**Patients and Methods:** Patients with BOT who underwent surgery at two institutions between January 2000 and June 2017 were included and categorized into training and validation cohorts. Univariate log rank test and Cox regression analysis were performed in the training cohort to identify prognostic factors, and a nomogram was developed to predict the recurrence rate. The model was validated by calculating the C-index and drawing the calibration curve and receiver operating curve (ROC).

**Conclusion:** In the multivariate Cox regression analysis, practice period, past history of benign ovarian disease, past history of benign breast disease, elevated CA125 levels, elevated CA199 levels, surgical methods, greater omentum resection, FIGO stage, postoperative pregnancy, and re-operation were independently associated with recurrence-free survival ( $p < 0.05$ ). The aforementioned prognostic factors were used to develop a nomogram. The nomogram demonstrated a good ability to predict the risk of recurrence (training cohort C-index: 0.866, validation cohort C-index: 0.920). The calibration curve suggested that the predicted recurrence-free survival was closely related to the actual recurrence. ROC analysis showed that the nomogram had a good discriminatory power with the area under curve between 0.776 and 0.956. The nomogram can predict the 1-, 3-, and 5-year recurrence-free survival of BOT patients undergoing fertility-preserving surgery. The predictive model can help guide surgical plans, postoperative monitoring, and prognostic evaluation of BOT patients.

**Keywords:** borderline ovarian tumor, fertility-preserving surgery, recurrence, disease-free survival, prediction model

## Introduction

Borderline ovarian tumor (BOT) is defined as “an ovarian tumor exhibiting an atypical epithelial proliferation greater than that seen in the benign counterpart but without destructive stromal invasion” by the World Health Organization.<sup>1</sup> It shows histopathological characteristics and clinical behavior between benign ovarian tumors and invasive epithelial ovarian cancers<sup>2</sup> and represents 10% to 20% of ovarian neoplasms.<sup>3</sup> Certain BOT belongs to the non-epithelial ovarian cancers, and include germ cell tumors, sex cord-stromal cell origin, small-cell carcinomas and sarcomas.<sup>4</sup> Pathologically, BOT has low malignant potential<sup>5,6</sup> and clinically, BOT is characterized by presentation at an earlier stage and younger age at the time of diagnosis (10 years earlier than ovarian cancer). Previous studies have revealed that 78.9% of BOT patients were diagnosed

at FIGO stage I and one-third of them were younger than 40 years<sup>7,8</sup> and even some patients were diagnosed with BOT during pregnancy.<sup>9</sup> Because of the pathological and clinical features, fertility-preserving surgery that preserves the uterus and at least a part of ovary can be considered for young patients who wish to retain their fertility and even for patients with advanced-stage BOT.<sup>2,10,11</sup>

Although BOT has a favorable prognosis, up to 25% of patients relapse or die from the disease.<sup>12</sup> A higher recurrence rate with a shorter recurrence interval has been recorded in BOT patients treated with fertility-sparing surgery as compared to patients treated with radical surgery.<sup>13–15</sup> Therefore, it is important to establish a prediction model to distinguish the population at a higher risk of recurrence after fertility-preserving surgery. This is essential to correctly identify candidates suitable for fertility-preserving surgery.

Nomogram is an ideal model that can simplify statistical predictive models into a single numerical estimate of the probability of a clinical event.<sup>16</sup> To date, there have been no published studies using a nomogram as a recurrence prediction model for BOT patients who undergo fertility-preserving surgeries. Therefore, the objective of this study was to develop a nomogram that could predict the probability of recurrence in these patients.

## Materials and Methods

### Study Population

In accordance with the Declaration of Helsinki, the patients had signed a consent when they were hospitalized, agreed to use clinical data and specimens for scientific research, and promised that their private information would not be disclosed. This study was approved by the Medical Ethical Committee of Xiangya Hospital (No.202005065) and was registered in the Chinese Clinical Trial Registry (ChiCTR2000033446). Clinical records of patients with BOT (diagnosis confirmed histopathologically) between January 2000 and June 2017 were retrieved from the information systems of two institutions (The First Affiliated Hospital of Hunan University of Medicine and Xiangya Hospital, Central South University). Patients from Xiangya Hospital were included into the training cohort, and patients from The First Affiliated Hospital of Hunan University of Medicine were included into the validation cohort.

### Inclusion and Exclusion Criteria

The inclusion criteria were defined as follows: (1) patients who underwent conservative surgical treatment, consisting of unilateral ovarian tumor resection, bilateral ovarian tumor resection, unilateral adnexal resection, or unilateral adnexal resection + contralateral ovarian tumor resection; (2) BOT patients with a definite postoperative pathological diagnosis; (3) patients with complete clinicopathological and follow-up data; and (4) patients who agreed to receive telephone interviews.

In addition, patients were excluded if they met the following exclusion criteria: (1) had missing clinical data and; (2) refused to follow up.

### Variables Definition

Disease-free survival (DFS) was defined as the time interval between the date of postoperative pathological diagnosis and the date of the last imaging examination without signs of recurrence, recorded in months. The practice period of the surgeon was recorded in years, and it was equal to the operation date of the patient from the time the surgeon first became an attending physician. Re-operation was defined as a comprehensive staging surgery performed after the first operation before tumor recurrence. The follow-up was terminated if there was any evidence of recurrence that was confirmed on imaging.

### Data Collection

The collected data included: (1) patient demographics like age, gravidity, breast disease history, and ovarian disease history; (2) clinical characteristics, including the FIGO stage (according to the International Federation of Gynecology and Obstetrics 2014 criteria<sup>17</sup>), tumor size (maximum diameter of tumor reported by CT or MRI or ultrasound), type of primary surgery, and postoperative pathological diagnosis; (3) follow-up content: details on treatment, relapse and

postoperative fertility, including postoperative adjuvant therapy, time to relapse, natural or assisted pregnancy, delivery way, delivery date, and pregnancy complications; (5) practice period of the primary surgeon.

## Model Development

Continuous variables, including age, practice period and tumor size were grouped into graded data at intervals of 10 years, 10 years, and 2 cm, respectively. The patients in the training cohort were divided into the recurrence and non-recurrence groups. We used SPSS 26.0 (IBM Co., Armonk, NY, USA) to compare the difference between the recurrence group and the non-recurrence group, categorical variables were analyzed using the Chi-square test or Fisher's exact test, and the variables that showed statistically significant results in the univariate Log rank test were subsequently included in the multivariate Cox regression model. Differences were considered significant at a level of  $P < 0.05$  and hazard ratios (HR) were represented with their 95% confidence intervals (95% CI). DFS curves were depicted using the Kaplan–Meier method and compared using the log rank test.

After identifying significant factors related to DFS through multivariate analyses ( $P < 0.05$ ), a nomogram for predicting the 1-, 3-, and 5-year DFS was constructed using the R v4.0 software (R Foundation for Statistical Computing, Vienna, Austria; <http://www.r-project.org/>) with the rms and survival package.

## Model Validation

Internal validation was performed using the Bootstrap method for repeated sampling 1000 times, and the calibration of the nomogram was evaluated by the Concordance index (C-index). The calibration curve was analyzed by plotting the nomogram predictions and the actual recurrence rates of BOT patients treated with fertility-preserving surgery. The range of C-index is 0.5–1. Closer the C-index is to 1, better the discrimination between the model prediction results and the reality. The receiver operating characteristic curve (ROC) was drawn, and the precision (sensitivity and specificity) of the model was evaluated by calculating the area under curve (AUC). Closer the AUC value is to 1, better is the model's discrimination.

External validation was performed using the data of the validation cohort. Time and region of data collection in the validation cohort were different from those in the training cohort, but the inclusion and exclusion criteria were the same.

## Delivery Methods and Recurrence

To investigate the relationship between the methods of delivery and recurrence, we used the Chi-square test of the four-grid to analyze if there was a significant difference in delivery methods between the recurrent and non-recurrent groups in the training cohort. A p-value of  $< 0.05$  was considered statistically significant.

## Results

### Patient Characteristics

A total of 386 BOT patients received primary surgical treatment between January 2000 and June 2017 in The First Affiliated Hospital of Hunan University of Medicine and Xiangya Hospital. Among them, 123 patients were unreachable by phone, 14 patients refused follow up, and 2 patients were successfully followed up, but the clinical data were missing. Finally, 247 BOT patients were included in this retrospective study. Among them, 204 patients from Xiangya Hospital were included in the training cohort and 43 patients from The First Affiliated Hospital of Hunan University of Medicine were included in the validation cohort. The ratio of the two groups was approximately 4.7:1. The demographic, clinical characteristics, and experimental results of the training and the validation cohorts were similar (Table 1).

### Predictive Factors for Recurrence in BOT Patients Treated with Fertility-Preserving Surgery

In the univariate Log rank test analysis, age, practice period, past history of benign ovarian disease, past history of benign breast disease, elevated CA125, elevated CA199, surgical methods, greater omentum resection, disease laterality, FIGO stage, pathological pattern, postoperative pregnancy, and re-operation were significant prognostic factors for DFS

**Table 1** Specimen Demographic, Clinical Characteristics

|  | Train Cohort (N=204); n (%) | Validation Cohort (N=43); n (%) | P      |
|--|-----------------------------|---------------------------------|--------|
| Age (years, mean±SD)                   | 32±9.192                    | 27±2.121                        | 0.226  |
| Median of follow-up period (months)    | 55                          | 61                              | 0.198  |
| Preoperative Delivery History          | 93 (45.59%)                 | 23 (53.49%)                     | <0.001 |
| Recurrence                             | 62 (30.39%)                 | 13 (30.23%)                     | 0.983  |
| FIGO stage                             |                             |                                 | 0.421  |
| Ia                                     | 108 (52.94%)                | 17 (39.53%)                     |        |
| Ib                                     | 56 (27.45%)                 | 14 (32.56%)                     |        |
| Ic                                     | 32 (15.69%)                 | 8 (18.60%)                      |        |
| II                                     | 4 (1.96%)                   | 2 (4.65%)                       |        |
| III                                    | 4 (1.96%)                   | 2 (4.65%)                       |        |
| Pathological Pattern                   |                             |                                 | <0.001 |
| Serous                                 | 102 (50.00%)                | 13 (30.23%)                     |        |
| Mucinous                               | 75 (36.76%)                 | 24 (55.81%)                     |        |
| Seromucinous                           | 21 (10.29%)                 | 0 (0.00%)                       |        |
| Endometrioid                           | 0 (0.00%)                   | 1 (2.33%)                       |        |
| Borderline Brenner tumor               | 0 (0.00%)                   | 1 (2.33%)                       |        |
| Others                                 | 6 (2.94%)                   | 4 (9.30%)                       |        |
| Surgical Methods                       |                             |                                 | 0.785  |
| UOTR                                   | 34 (16.67%)                 | 8 (18.60%)                      |        |
| BOTR                                   | 39 (19.11%)                 | 8 (18.60%)                      |        |
| UAR                                    | 86 (42.16%)                 | 15 (34.88%)                     |        |
| UAR+COTR                               | 45 (22.06%)                 | 12 (27.91%)                     |        |
| Surgical Type                          |                             |                                 | 0.064  |
| Laparoscope                            | 93 (45.59%)                 | 13 (30.23%)                     |        |
| Laparotomy                             | 111 (54.41%)                | 30 (69.74%)                     |        |
| CA125 Elevated                         | 49 (24.02%)                 | 12 (27.91%)                     | 0.591  |
| CA199 Elevated                         | 18 (8.82%)                  | 4 (9.30%)                       | 0.920  |
| CEA Elevated                           | 5 (2.45%)                   | 0 (0.00%)                       | 0.300  |
| Pelvic Lymph Node Resection            | 1 (0.49%)                   | 9 (20.93%)                      | <0.001 |
| Appendix Abnormal Appearance           | 0 (0.00%)                   | 0 (0.00%)                       |        |
| Greater Omentum Resection              | 62 (30.39%)                 | 15 (34.88%)                     | 0.563  |
| Lesion Region                          |                             |                                 | 0.376  |
| Unilateral                             | 124 (60.78%)                | 23 (53.49%)                     |        |
| Bilateral                              | 80 (39.22%)                 | 20 (46.51%)                     |        |
| Hormone Drugs                          | 5 (2.45%)                   | 7 (16.28%)                      | <0.001 |
| Postoperative Chemoradiotherapy        | 28 (13.73%)                 | 6 (13.95%)                      | 0.403  |
| Postoperative Pregnancy                | 50 (24.51%)                 | 13 (30.23%)                     | 0.434  |
| Past History of Breast Benign Disease  | 27 (13.24%)                 | 13 (30.23%)                     | 0.006  |
| Past History of Ovarian Benign Disease | 52 (25.49%)                 | 10 (23.26%)                     | 0.759  |
| Re-operation                           | 40 (19.61%)                 | 12 (27.90%)                     | 0.225  |

**Abbreviations:** UOTR, unilateral ovarian tumor resection; BOTR, bilateral ovarian tumor resection; UAR, unilateral adnexa resection; COTR, contralateral ovarian tumor resection.

(Table 2). In the multivariate COX regression analysis, the independent prognostic factors predicting the DFS comprised all the above, except age and disease laterality (Table 3).

Kaplan–Meier survival curves demonstrated that lower practice period, past history of benign ovarian or breast disease, elevated CA125 or CA199 levels, complex surgical method without greater omentum resection, higher FIGO stage, postoperative pregnancy, and re-operation had worse DFS (Figure 1).

**Table 2** Univariate Log Rank Test Analysis

| Variable                              | $\chi^2$ | P value          |
|---------------------------------------|----------|------------------|
| Age                                   | 64.030   | <b>0.009</b>     |
| Practice period                       | 101.047  | <b>&lt;0.001</b> |
| Preoperative delivery history         | 0.018    | 0.893            |
| Past history of ovarian begin history | 21.925   | <b>&lt;0.001</b> |
| Past history of breast begin history  | 29.268   | <b>&lt;0.001</b> |
| CA125 elevated                        | 30.899   | <b>&lt;0.001</b> |
| CA199 elevated                        | 12.584   | <b>&lt;0.001</b> |
| CEA elevated                          | 2.328    | 0.312            |
| Tumor size                            | 6.692    | 0.669            |
| Surgical methods                      | 21.133   | <b>&lt;0.001</b> |
| Surgical type                         | 1.574    | 0.210            |
| Pelvic lymph node resection           | 0.984    | 0.321            |
| Greater Omentum resection             | 11.937   | <b>0.001</b>     |
| Unilateral or bilateral lesion        | 8.793    | <b>0.003</b>     |
| FIGO stage                            | 31.177   | <b>&lt;0.001</b> |
| Pathological pattern                  | 8.976    | <b>0.030</b>     |
| Postoperative chemoradiotherapy       | 0.042    | 0.838            |
| Postoperative pregnancy               | 18.328   | <b>&lt;0.001</b> |
| Hormone drugs                         | 0.467    | 0.494            |
| Re-operation                          | 18.917   | <b>&lt;0.001</b> |

**Note:** P value less than 0.05 is indicated by bold.

## Development and Validation of the Predictive Nomogram

All ten variables with statistical significance noted in the multivariable analysis for predicting the rate of recurrence were chosen to develop the nomogram (Figure 2). The C-index of the nomogram was 0.866 (95% CI: 0.824–0.908) in the training cohort. The model manifested a good degree of calibration. The AUC of the 1-, 3-, and 5-year DFS were 0.776, 0.895, and 0.940, respectively, in the training cohort (Figure 3).

The performance of the nomogram was also evaluated in the validation cohort, with a C-index of 0.920 (95% CI: 0.824–1.000), indicating that the model had a good discrimination. In addition, the AUC of the 1-, 3-, and 5-year DFS were 0.952, 0.954, and 0.956, respectively, indicating good predictive ability of the model (Figure 4).

## Delivery Methods and Recurrence

In the training cohort, there were 10 natural births and 20 cesarean sections in the recurrence group, and 16 natural births and 4 cesarean sections in the non-recurrence group. After Chi-square test, it was found that patients delivering with cesarean section post the fertility-preserving surgery were more likely to have tumor recurrence ( $P=0.003$ ).

## Discussion

One of the clinical characteristics of BOT is that it tends to occur in women of childbearing age, making fertility-preserving surgery widely used in BOT patients, even in patients with advanced-stage disease.<sup>10,11,18</sup> However, several studies have reported that fertility-preserving surgery is associated with an increased risk of recurrence.<sup>15,19</sup> Therefore, it is imperative to predict the probability of recurrence in these patients undergoing fertility-preserving surgery. In this study, we developed a nomogram that was capable of predicting tumor recurrence probability in BOT patients who were treated with fertility-preserving surgery. All the predictive factors used in the model are closely related to clinical practice and are easy to obtain and use; thereby making this model potentially popular in routine clinical practice.

In the nomogram, re-operation is the most important protective factor; hence, we recommend that BOT patients with proven high-risk factors for recurrence should undergo comprehensive staging surgery after successful postoperative delivery. Patients who underwent unilateral ovarian tumor resection were most likely to experience a relapse, while


**Table 3** Multivariate Cox Proportional Hazards Regression Analysis

|  | <b>B</b> | <b>SE</b> | <b>Wald <math>\chi^2</math></b> | <b>P value</b> | <b>HR (95% CI)</b>   |
|--|----------|-----------|---------------------------------|----------------|----------------------|
| Age (10–19y)                               |          |           | 4.63                            | 0.327          |                      |
| 20–29y                                     | –0.896   | 0.819     | 1.197                           | 0.274          | 0.408 (0.082,2.032)  |
| 30–39y                                     | –0.118   | 0.849     | 0.019                           | 0.889          | 0.888 (0.168,4.694)  |
| 40–49y                                     | –0.6     | 0.924     | 0.421                           | 0.517          | 0.549 (0.090,3.361)  |
| 50–59y                                     | –8.269   | 769.852   | <0.001                          | 0.991          | <0.001               |
| Practice period (0–10y)                    |          |           | 12.119                          | <b>0.007</b>   |                      |
| 10–20y                                     | –0.967   | 0.404     | 5.727                           | <b>0.017</b>   | 0.380 (0.172,0.839)  |
| 20–29y                                     | –1.38    | 0.501     | 7.602                           | <b>0.006</b>   | 0.251 (0.094,0.671)  |
| 30–39y                                     | 0.327    | 0.824     | 0.158                           | 0.691          | 1.387 (0.276,6.977)  |
| Past history of ovarian begin history (no) |          |           |                                 |                |                      |
| Yes  | 0.823    | 0.34      | 5.863                           | <b>0.015</b>   | 2.277 (1.170,4.433)  |
| Past history of breast begin history (no)  |          |           |                                 |                |                      |
| Yes  | 1.08     | 0.334     | 10.444                          | <b>0.001</b>   | 2.946 (1.530,5.672)  |
| CA125 elevated (no)                        |          |           |                                 |                |                      |
| Yes  | 0.858    | 0.345     | 6.195                           | <b>0.013</b>   | 2.358 (1.200,4.632)  |
| CA199 elevated (no)                        |          |           |                                 |                |                      |
| Yes  | 1.134    | 0.4       | 8.018                           | <b>0.005</b>   | 3.108 (1.418,6.814)  |
| Surgical methods (UOTR)                    |          |           | 12.125                          | <b>0.007</b>   |                      |
| BOTR                                       | 1.65     | 1.208     | 1.866                           | 0.172          | 5.208 (0.488,55.558) |
| UAR  | –1.023   | 0.51      | 4.025                           | <b>0.045</b>   | 0.359 (0.132,0.977)  |
| UAR+COTR                                   | 2.275    | 1.189     | 3.662                           | 0.056          | 9.724 (0.946,99.919) |
| Greater Omentum resection (no)             |          |           |                                 |                |                      |
| Yes  | –1.162   | 0.487     | 5.696                           | <b>0.017</b>   | 0.313 (0.120,0.812)  |
| Unilater or bilateral lesion (Unilateral)  |          |           |                                 |                |                      |
| Bilateral                                  | –1.071   | 1.158     | 0.855                           | 0.355          | 0.343 (0.035,3.316)  |
| FIGO stage (Ia)                            |          |           | 12.296                          | <b>0.015</b>   |                      |
| Ib   | –0.323   | 0.957     | 0.114                           | 0.736          | 0.724 (0.111,4.726)  |
| Ic   | –0.914   | 0.873     | 1.098                           | 0.295          | 0.401 (0.072, 2.217) |
| II   | 2.112    | 0.746     | 8.019                           | <b>0.005</b>   | 8.261 (1.916,35.626) |
| III  | 0.163    | 1.03      | 0.025                           | 0.874          | 1.177 (0.156,8.857)  |
| Pathological pattern (serousity)           |          |           | 2.912                           | 0.405          |                      |
| Mucinousness                               | 0.555    | 0.334     | 2.763                           | 0.096          | 1.741 (0.905, 3.349) |
| Serous mucinity                            | –11.857  | 284.218   | 0.002                           | 0.967          | <0.001               |
| others                                     | –0.166   | 1.094     | 0.023                           | 0.88           | 0.847 (0.099,7.233)  |
| Postoperative pregnancy (no)               |          |           |                                 |                |                      |
| Yes  | 0.704    | 0.319     | 4.864                           | <b>0.027</b>   | 2.022 (1.082,3.782)  |
| Re-operation (no)                          |          |           |                                 |                |                      |
| Yes  | –2.63    | 1.099     | 5.722                           | <b>0.017</b>   | 0.072 (0.008,0.622)  |


**Note:** P value less than 0.05 is indicated by bold.

**Abbreviations:** B, regression coefficient; SE, standard error; UOTR, unilateral ovarian tumor resection; BOTR, bilateral ovarian tumor resection; UAR, unilateral adnexa resection; COTR, contralateral ovarian tumor resection.

patients with unilateral adnexal resection were the least likely. It is, therefore, suggested that unilateral adnexal resection should be performed in patients with fertility preservation needs if the contralateral ovary function is normal. We also found that unilateral or bilateral lesions were not associated with recurrence. Peritoneal implants have prognostic significance, and the most common sites of implants include the omentum and peritoneal surfaces; therefore, omentectomy was recommended in the comprehensive surgical staging.<sup>20</sup> However, another study, including 539 patients with BOT from 14 institutions concluded that comprehensive surgical staging was not necessary for borderline ovarian tumors.<sup>21</sup> We also believe that a comprehensive surgical staging with at least greater omentum resection may be beneficial for BOT patients. Unfortunately, data on cytologic washings and peritoneal biopsies were lacking and not included in this study, but greater omentum resection was shown to be a protective factor. Based on the study findings, it



**Figure 1** Kaplan-Meier disease-free survival curve of variable in training cohort.




**Figure 2** BOT patients treated with fertility-preserving surgery with nomogram including 10 readily available clinical characteristics to predict 1-, 3-, 5-year DFS.

is recommended that the omentum be removed at the same time when fertility-preserving surgery is performed. However, further validation of this is required with randomized control or higher-level studies to prove the benefit in BOT patients.

This study also introduces several novel predictors of recurrence. The practice period of surgeon has a considerable effect on the recurrence of BOT. Longer is the practice period lower is the risk of recurrence. Past history of benign ovarian or breast tumor has also shown to increase the probability of BOT recurrence. The specific mechanism for this, however, is unclear, and we suggest a possible relationship to hormones.

Age has been considered to be a predictive factor for the recurrence of BOT in many studies, with some studies reporting that younger patients have a worse outcome,<sup>22</sup> while others reported that older patients were far worse.<sup>23</sup> Unlike the previous studies, age was not found to be a predictor of recurrence in this study. This was possibly because the age of the patients undergoing fertility-preserving surgery was relatively lower, and the effect of age on tumor recurrence was not demonstrable. The primary surgery type performed by laparoscopy or by laparotomy is an independent factor for prediction of the risk of recurrence in our study, consistent with previous studies.<sup>24,25</sup>

Postoperative pregnancies were recorded in only a subset of patients, so the delivery methods were not included in the model and were analyzed using the Chi-square test. The result showed that cesarean section was significantly correlated with tumor recurrence. Although the sample size is limited, we should still pay attention to it. It is not recommended to




**Figure 3** Calibration curve and the AUC of 1-, 3-, 5-year DFS in training cohort. **(A)** Calibration curve. The black dots are the scatter points on the calibration curve, representing the actual versus predicted incidence. The gray line is the reference line, that the predicted probability equals the actual probability. The two lines closely overlap, suggesting that the nomogram accurately estimated the recurrence probability of our patient cohort. **(B)** The AUC of 1-, 3-, 5-year DFS respectively.

relax the indications of cesarean section, to avoid tumor recurrence and metastasis in the pelvic cavity. Further studies are required on the relationship between the method of delivery and tumor recurrence.

The clinical prediction model of recurrence in BOT patients treated with fertility-preserving surgery conforms to the requirements of precision medicine and aims to achieve a better balance between the fertility requirements of the patients and the control of the disease. The AUC of our model is very high, indicating that this model can accurately predict the recurrence of BOT patients treated with fertility-preserving surgery. However, some limitations need to be acknowledged. The small number of ROC samples resulted in an unsmooth curve, especially in validation cohort, mainly due to the small number of BOT patients who relapsed within 1 year, which is also in line with the tumor biological behavior of BOT. Moreover, Due to limited data, the effects of immunohistochemistry and special pathological behaviors of tumor such as papillary structure and peritoneal implantation on the recurrence of BOT patients were not analyzed in this study. In addition, a small sample size and single-center characteristics may also affect the accuracy of this study. We hope that in the future, this nomogram can have an external multicenter validation.

## Conclusion

The nomogram, designed in this article, is a good recurrence prediction model for BOT patients treated with fertility-preserving surgery. A high C-index and AUC indicate good discrimination and differentiation of the model. We recommend predicting the risk of recurrence for all BOT patients who want to preserve their fertility, and high-risk patients should undergo comprehensive staging surgery after successful postoperative delivery to avoid recurrence. Unilateral adnexal resection is the best surgical procedure for patients if the contralateral ovary function is normal.



**Figure 4** Calibration curve and the AUC of 1-, 3-, 5-year DFS in validation cohort. **(A)** Calibration curve for the nomogram. **(B)** The AUC of 1-, 3-, 5-year DFS respectively.

## Acknowledgments

Thanks for all patients who provided clinical data for this article. We also would like to thank Editage for English language editing.

## Disclosure

The authors report no conflicts of interest in this work.

## References

- Mccluggage WG. The pathology of and controversial aspects of ovarian borderline tumours. *Curr Opin Oncol.* 2010;22(5):462–472. doi:10.1097/CCO.0b013e32833b0dc1
- Matsuo K, Machida H, Mandelbaum RS, et al. Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: difference in characteristics and outcomes. *Gynecol Oncol.* 2019;153(2):230–237. doi:10.1016/j.ygyno.2019.02.003
- Lu Z, Li B, Gu C. Outcomes of fertility-sparing surgery for stage II and III serous borderline ovarian tumors. *J Int Med Res.* 2019;47(10):4895–4903. doi:10.1177/0300060519865850
- Boussios S, Zarkavelis G, Seraj E, Zerdes I, Tatsi K, Pentheroudakis G. Non-epithelial ovarian cancer: elucidating uncommon gynaecological malignancies. *Anticancer Res.* 2016;36(10):5031–5042. doi:10.21873/anticancer.11072
- Classification and staging of malignant tumours in the female pelvis. *Acta Obstet Gynecol Scand.* 1971;50(1):1–7. doi:10.3109/00016347109157278
- Silverberg SG, Bell DA, Kurman RJ, et al. Borderline ovarian tumors: key points and workshop summary. *Hum Pathol.* 2004;35(8):910–917. doi:10.1016/j.humpath.2004.03.003
- Sherman ME, Berman J, Birrer MJ, et al. Current challenges and opportunities for research on borderline ovarian tumors. *Hum Pathol.* 2004;35(8):961–970. doi:10.1016/j.humpath.2004.03.007
- Sherman ME, Mink PJ, Curtis R, et al. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. *Cancer.* 2004;100(5):1045–1052. doi:10.1002/cncr.20080
- Boussios S, Moschetta M, Tatsi K, Tsiouris AK, Pavlidis N. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: diagnostic and therapeutic perspectives. *J Adv Res.* 2018;12:1–9. doi:10.1016/j.jare.2018.02.006
- Uzan C, Nikpayam M, Ribassin-Majed L, et al. Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments. *Ann Oncol.* 2014;25(7):1312–1319. doi:10.1093/annonc/mdu139

11. du Bois A, Trillsch F, Mahner S, Heitz F, Harter P. Management of borderline ovarian tumors. *Ann Oncol.* 2016;27(Suppl 1):i20–i22. doi:10.1093/annonc/mdw090
12. Morice P, Uzan C, Fauvet R, Gouy S, Duvillard P, Darai E. Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence. *Lancet Oncol.* 2012;13(3):e103–e115. doi:10.1016/S1470-2045(11)70288-1
13. du Bois A, Ewald-Riegler N, de Gregorio N, et al. Borderline tumours of the ovary: a cohort study of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) study group. *Eur J Cancer.* 2013;49(8):1905–1914. doi:10.1016/j.ejca.2013.01.035
14. Guvenal T, Dursun P, Hasdemir PS, et al. Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish gynecologic oncology group study. *Gynecol Oncol.* 2013;131(3):546–550. doi:10.1016/j.ygyno.2013.08.038
15. Fang C, Zhao L, Chen X, Yu A, Xia L, Zhang P. The impact of clinicopathologic and surgical factors on relapse and pregnancy in young patients (<=40 years old) with borderline ovarian tumors. *BMC Cancer.* 2018;18(1):1147. doi:10.1186/s12885-018-4932-2
16. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. *J Clin Oncol.* 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.9791
17. Prat J. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. *J Gynecol Oncol.* 2015;26(2):87–89. doi:10.3802/jgo.2015.26.2.87
18. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Surgical management of borderline ovarian tumors: the role of fertility-sparing surgery. *Gynecol Oncol.* 2009;113(1):75–82. doi:10.1016/j.ygyno.2008.12.034
19. Sun H, Chen X, Zhu T, Liu N, Yu A, Wang S. Age-dependent difference in impact of fertility preserving surgery on disease-specific survival in women with stage I borderline ovarian tumors. *J Ovarian Res.* 2018;11(1):54. doi:10.1186/s13048-018-0423-y
20. Fotopoulou C, Schumacher G, Schefold JC, Denkert C, Lichtenegger W, Sehouli J. Systematic evaluation of the intraoperative tumor pattern in patients with borderline tumor of the ovary. *Int J Gynecol Cancer.* 2009;19(9):1550–1555. doi:10.1111/IGC.0b013e3181a84699
21. Kristensen GS, Schledermann D, Mogensen O, Jochumsen KM. The value of random biopsies, omentectomy, and hysterectomy in operations for borderline ovarian tumors. *Int J Gynecol Cancer.* 2014;24(5):874–879. doi:10.1097/IGC.0000000000000140
22. Karlsen N, Karlsen MA, Hogdall E, Nedergaard L, Christensen IJ, Hogdall C. Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT). *Gynecol Oncol.* 2016;142(1):50–53. doi:10.1016/j.ygyno.2016.05.005
23. Song T, Lee YY, Choi CH, et al. Risk factors for progression to invasive carcinoma in patients with borderline ovarian tumors. *Int J Gynecol Cancer.* 2014;24(7):1206–1214. doi:10.1097/IGC.0000000000000216
24. Odegaard E, Staff AC, Langebrekke A, Engh V, Onsrud M. Surgery of borderline tumors of the ovary: retrospective comparison of short-term outcome after laparoscopy or laparotomy. *Acta Obstet Gynecol Scand.* 2007;86(5):620–626. doi:10.1080/00016340701286934
25. Jiao X, Hu J, Zhu L. Prognostic factors for recurrence after fertility-preserving surgery in patients with borderline ovarian tumors: a systematic review and meta-analysis of observational studies. *Int J Gynecol Cancer.* 2017;27(9):1833–1841. doi:10.1097/IGC.0000000000001092

International Journal of General Medicine

Dovepress

## Publish your work in this journal

The International Journal of General Medicine is an international, peer-reviewed open-access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-general-medicine-journal>